MSD International GmbH (Singapore Branch)September 3, 2021

FDA 483 - MSD International GmbH (Singapore Branch) - September 03, 2021

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore MSD International GmbH (Singapore Branch)

Record Details

MSD International GmbH Singapore Branch, a sterile drug product manufacturer in Singapore, was cited for significant deficiencies during an FDA inspection. Observations included failures in aseptic processing procedures, lack of assurance in manufacturing process consistency, inadequate written procedures for foreign matter investigation, and insufficient verification of supplier COAs. Additionally, the facility exhibited design and maintenance issues, posing risks to product quality and sterility.

Company: MSD International GmbH (Singapore Branch)
Inspection Date: September 3, 2021
Product Type: Drugs
Office: Division of Clinical Evidence and Analysis 1 (Clinical Policy and Quality)
People: Zhihao Peter Qiu (issuing_officer)
Wendy Guat Hoon Tan (investigator)

Open in Dashboard

ID · 61654fcd-a8cd-4a95-99b8-a4a44ce2cf88